Ligand Pharmaceuticals LGND AT220 — Gross carrying value
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept lgnd:FinancialRoyaltyAssetsGross.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's at220 — gross carrying value.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's AT220 — gross carrying value?
- Ligand Pharmaceuticals (LGND) reported AT220 — gross carrying value of $4.78M in Q1 2026.
- What does AT220 — gross carrying value mean?
- This metric represents the total historical cost or initial valuation of royalty-based intangible assets associated with the AT220 product line before any adjustments for impairment or amortization. It serves as a baseline indicator of the capital invested or the acquisition value attributed to the intellectual property rights within this specific segment. Monitoring this value helps investors understand the scale of the company's asset base dedicated to this particular therapeutic or technology stream.